A little-known Chinese company made a drug that beat the world’s biggest selling medicine
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...
Pharm Exec16h
FDA Grants Priority Review to Merck’s Keytruda for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...
Cure Today13h
FDA Accepts Priority Review for Pre- and Postsurgical Keytruda in HNSCC
The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...
Merck’s application for keytruda in HNSCC granted priority review by FDA
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
The Pharma Letter17h
FDA grants priority review to Merck’s sBLA for Keytruda
The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...
Pfizer: What The Summit Therapeutics Deal Brings
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
devdiscourse4h
Healthcare Headlines: From West Bank Violence to Overdose Decline
The World Health Organization raises alarms over increased West Bank violence affecting healthcare. In Congo, over 50 die due ...
Medicenna Therapeutics reports clinical data from ABILITY-1 study of MDNA11
Medicenna Therapeutics (MDNA) announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in ...
Cure Today7d
Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma
Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...
GlobalData on MSN1d
Pfizer sets sights on Summit’s bispecific in combo with its ADCs
Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.